Safety and biomarker effects of solanezumab in patients with Alzheimer's disease

Martin Farlow, Steven E. Arnold, Christopher H. Van Dyck, Paul S. Aisen, B. Joy Snider, Anton P. Porsteinsson, Stuart Friedrich, Robert A. Dean, Celedon Gonzales, Gopalan Sethuraman, Ronald B. Demattos, Richard Mohs, Steven M. Paul, Eric R. Siemers

Research output: Contribution to journalArticle

165 Citations (Scopus)

Abstract

Objectives: To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of 12 weekly infusions of solanezumab, an anti-β-amyloid (Aβ) antibody, in patients with mild-to-moderate Alzheimer's disease. Cognitive measures were also obtained. Methods: In this phase 2, randomized, double-blind, placebo-controlled clinical trial, 52 patients with Alzheimer's disease received placebo or antibody (100 mg every 4 weeks, 100 mg weekly, 400 mg every 4 weeks, or 400 mg weekly) for 12 weeks. Safety and biomarker evaluations continued until 1 year after randomization. Both magnetic resonance imaging and cerebrospinal fluid (CSF) examinations were conducted at baseline and after the active treatment period. The Aβ concentrations were measured in plasma and CSF, and the Alzheimer's Disease Assessment Scale-cognitive portion was administered. Results: Clinical laboratory values, CSF cell counts, and magnetic resonance imaging scans were unchanged by treatment, and no adverse events could be clearly related to antibody administration. Total (bound to antibody and unbound) Aβ 1-40 and Aβ 1-42 in plasma increased in a dose-dependent manner. Antibody treatment similarly increased total Aβ 1-40 and Aβ 1-42 in CSF. For patients taking 400 mg weekly, antibody treatment decreased unbound Aβ 1-40 in CSF (P <.01), but increased unbound Aβ 1-42 in CSF in a dose-dependent manner. The Alzheimer's Disease Assessment Scale-cognitive portion was unchanged after the 12-week antibody administration. Conclusions: Antibody administration was well tolerated with doses up to 400 mg weekly. The dose-dependent increase in unbound CSF Aβ 1-42 suggests that this antibody may shift Aβ equilibria sufficiently to mobilize Aβ 1-42 from amyloid plaques.

Original languageEnglish
Pages (from-to)261-271
Number of pages11
JournalAlzheimer's and Dementia
Volume8
Issue number4
DOIs
StatePublished - Jul 2012

Fingerprint

solanezumab
Alzheimer Disease
Biomarkers
Cerebrospinal Fluid
Safety
Antibodies
Placebos
Magnetic Resonance Imaging
Controlled Clinical Trials
Amyloid Plaques
Therapeutics

Keywords

  • β-amyloid
  • Aβ monoclonal antibody
  • Alzheimer's disease
  • Cerebrospinal fluid immunotherapy
  • LY2062430
  • Solanezumab

ASJC Scopus subject areas

  • Health Policy
  • Epidemiology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

Farlow, M., Arnold, S. E., Van Dyck, C. H., Aisen, P. S., Snider, B. J., Porsteinsson, A. P., ... Siemers, E. R. (2012). Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimer's and Dementia, 8(4), 261-271. https://doi.org/10.1016/j.jalz.2011.09.224

Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. / Farlow, Martin; Arnold, Steven E.; Van Dyck, Christopher H.; Aisen, Paul S.; Snider, B. Joy; Porsteinsson, Anton P.; Friedrich, Stuart; Dean, Robert A.; Gonzales, Celedon; Sethuraman, Gopalan; Demattos, Ronald B.; Mohs, Richard; Paul, Steven M.; Siemers, Eric R.

In: Alzheimer's and Dementia, Vol. 8, No. 4, 07.2012, p. 261-271.

Research output: Contribution to journalArticle

Farlow, M, Arnold, SE, Van Dyck, CH, Aisen, PS, Snider, BJ, Porsteinsson, AP, Friedrich, S, Dean, RA, Gonzales, C, Sethuraman, G, Demattos, RB, Mohs, R, Paul, SM & Siemers, ER 2012, 'Safety and biomarker effects of solanezumab in patients with Alzheimer's disease', Alzheimer's and Dementia, vol. 8, no. 4, pp. 261-271. https://doi.org/10.1016/j.jalz.2011.09.224
Farlow, Martin ; Arnold, Steven E. ; Van Dyck, Christopher H. ; Aisen, Paul S. ; Snider, B. Joy ; Porsteinsson, Anton P. ; Friedrich, Stuart ; Dean, Robert A. ; Gonzales, Celedon ; Sethuraman, Gopalan ; Demattos, Ronald B. ; Mohs, Richard ; Paul, Steven M. ; Siemers, Eric R. / Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. In: Alzheimer's and Dementia. 2012 ; Vol. 8, No. 4. pp. 261-271.
@article{4135fa2261a34f279a7b3f8a0c5c60c4,
title = "Safety and biomarker effects of solanezumab in patients with Alzheimer's disease",
abstract = "Objectives: To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of 12 weekly infusions of solanezumab, an anti-β-amyloid (Aβ) antibody, in patients with mild-to-moderate Alzheimer's disease. Cognitive measures were also obtained. Methods: In this phase 2, randomized, double-blind, placebo-controlled clinical trial, 52 patients with Alzheimer's disease received placebo or antibody (100 mg every 4 weeks, 100 mg weekly, 400 mg every 4 weeks, or 400 mg weekly) for 12 weeks. Safety and biomarker evaluations continued until 1 year after randomization. Both magnetic resonance imaging and cerebrospinal fluid (CSF) examinations were conducted at baseline and after the active treatment period. The Aβ concentrations were measured in plasma and CSF, and the Alzheimer's Disease Assessment Scale-cognitive portion was administered. Results: Clinical laboratory values, CSF cell counts, and magnetic resonance imaging scans were unchanged by treatment, and no adverse events could be clearly related to antibody administration. Total (bound to antibody and unbound) Aβ 1-40 and Aβ 1-42 in plasma increased in a dose-dependent manner. Antibody treatment similarly increased total Aβ 1-40 and Aβ 1-42 in CSF. For patients taking 400 mg weekly, antibody treatment decreased unbound Aβ 1-40 in CSF (P <.01), but increased unbound Aβ 1-42 in CSF in a dose-dependent manner. The Alzheimer's Disease Assessment Scale-cognitive portion was unchanged after the 12-week antibody administration. Conclusions: Antibody administration was well tolerated with doses up to 400 mg weekly. The dose-dependent increase in unbound CSF Aβ 1-42 suggests that this antibody may shift Aβ equilibria sufficiently to mobilize Aβ 1-42 from amyloid plaques.",
keywords = "β-amyloid, Aβ monoclonal antibody, Alzheimer's disease, Cerebrospinal fluid immunotherapy, LY2062430, Solanezumab",
author = "Martin Farlow and Arnold, {Steven E.} and {Van Dyck}, {Christopher H.} and Aisen, {Paul S.} and Snider, {B. Joy} and Porsteinsson, {Anton P.} and Stuart Friedrich and Dean, {Robert A.} and Celedon Gonzales and Gopalan Sethuraman and Demattos, {Ronald B.} and Richard Mohs and Paul, {Steven M.} and Siemers, {Eric R.}",
year = "2012",
month = "7",
doi = "10.1016/j.jalz.2011.09.224",
language = "English",
volume = "8",
pages = "261--271",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Safety and biomarker effects of solanezumab in patients with Alzheimer's disease

AU - Farlow, Martin

AU - Arnold, Steven E.

AU - Van Dyck, Christopher H.

AU - Aisen, Paul S.

AU - Snider, B. Joy

AU - Porsteinsson, Anton P.

AU - Friedrich, Stuart

AU - Dean, Robert A.

AU - Gonzales, Celedon

AU - Sethuraman, Gopalan

AU - Demattos, Ronald B.

AU - Mohs, Richard

AU - Paul, Steven M.

AU - Siemers, Eric R.

PY - 2012/7

Y1 - 2012/7

N2 - Objectives: To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of 12 weekly infusions of solanezumab, an anti-β-amyloid (Aβ) antibody, in patients with mild-to-moderate Alzheimer's disease. Cognitive measures were also obtained. Methods: In this phase 2, randomized, double-blind, placebo-controlled clinical trial, 52 patients with Alzheimer's disease received placebo or antibody (100 mg every 4 weeks, 100 mg weekly, 400 mg every 4 weeks, or 400 mg weekly) for 12 weeks. Safety and biomarker evaluations continued until 1 year after randomization. Both magnetic resonance imaging and cerebrospinal fluid (CSF) examinations were conducted at baseline and after the active treatment period. The Aβ concentrations were measured in plasma and CSF, and the Alzheimer's Disease Assessment Scale-cognitive portion was administered. Results: Clinical laboratory values, CSF cell counts, and magnetic resonance imaging scans were unchanged by treatment, and no adverse events could be clearly related to antibody administration. Total (bound to antibody and unbound) Aβ 1-40 and Aβ 1-42 in plasma increased in a dose-dependent manner. Antibody treatment similarly increased total Aβ 1-40 and Aβ 1-42 in CSF. For patients taking 400 mg weekly, antibody treatment decreased unbound Aβ 1-40 in CSF (P <.01), but increased unbound Aβ 1-42 in CSF in a dose-dependent manner. The Alzheimer's Disease Assessment Scale-cognitive portion was unchanged after the 12-week antibody administration. Conclusions: Antibody administration was well tolerated with doses up to 400 mg weekly. The dose-dependent increase in unbound CSF Aβ 1-42 suggests that this antibody may shift Aβ equilibria sufficiently to mobilize Aβ 1-42 from amyloid plaques.

AB - Objectives: To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of 12 weekly infusions of solanezumab, an anti-β-amyloid (Aβ) antibody, in patients with mild-to-moderate Alzheimer's disease. Cognitive measures were also obtained. Methods: In this phase 2, randomized, double-blind, placebo-controlled clinical trial, 52 patients with Alzheimer's disease received placebo or antibody (100 mg every 4 weeks, 100 mg weekly, 400 mg every 4 weeks, or 400 mg weekly) for 12 weeks. Safety and biomarker evaluations continued until 1 year after randomization. Both magnetic resonance imaging and cerebrospinal fluid (CSF) examinations were conducted at baseline and after the active treatment period. The Aβ concentrations were measured in plasma and CSF, and the Alzheimer's Disease Assessment Scale-cognitive portion was administered. Results: Clinical laboratory values, CSF cell counts, and magnetic resonance imaging scans were unchanged by treatment, and no adverse events could be clearly related to antibody administration. Total (bound to antibody and unbound) Aβ 1-40 and Aβ 1-42 in plasma increased in a dose-dependent manner. Antibody treatment similarly increased total Aβ 1-40 and Aβ 1-42 in CSF. For patients taking 400 mg weekly, antibody treatment decreased unbound Aβ 1-40 in CSF (P <.01), but increased unbound Aβ 1-42 in CSF in a dose-dependent manner. The Alzheimer's Disease Assessment Scale-cognitive portion was unchanged after the 12-week antibody administration. Conclusions: Antibody administration was well tolerated with doses up to 400 mg weekly. The dose-dependent increase in unbound CSF Aβ 1-42 suggests that this antibody may shift Aβ equilibria sufficiently to mobilize Aβ 1-42 from amyloid plaques.

KW - β-amyloid

KW - Aβ monoclonal antibody

KW - Alzheimer's disease

KW - Cerebrospinal fluid immunotherapy

KW - LY2062430

KW - Solanezumab

UR - http://www.scopus.com/inward/record.url?scp=84863221661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863221661&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2011.09.224

DO - 10.1016/j.jalz.2011.09.224

M3 - Article

VL - 8

SP - 261

EP - 271

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 4

ER -